WATERTOWN, Mass, March 16, 2026 (GLOBE NEWSWIRE) — EyePoint, Inc. (Nasdaq: EYPT), an organization dedicated to creating and commercializing therapeutics to assist reinforce the lives of sufferers with critical retinal sicknesses, nowadays introduced that the Corporate granted non-statutory inventory choices to new staff as inducement awards outdoor the Corporate’s 2023 Lengthy-Time period Incentive Plan based on NASDAQ Record Rule 5635(c)(4).
The Corporate granted inventory choices to buy as much as an combination of 20,000 stocks of EyePoint commonplace inventory to 6 new staff. The inventory choices have been granted on March 13, 2026. The grants have been authorized via the Reimbursement Committee and made as an inducement subject matter to each and every worker getting into into employment with EyePoint based on NASDAQ Record Rule 5635(c)(4). The choice awards have an workout worth of $13.20 in step with percentage, the last worth of EyePoint’s commonplace inventory on March 13, 2026. The choices have a ten-year time period and vest over 4 years, with 25% of the unique selection of stocks vesting at the first anniversary of the acceptable worker’s date of grant and the remaining vesting in equivalent per thirty days installments over the next 3 years. Vesting of the choices is topic to the worker’s persisted provider with EyePoint during the acceptable vesting dates.
About EyePoint
EyePoint, Inc. (Nasdaq: EYPT) is a clinical-stage biopharmaceutical corporate dedicated to creating and commercializing leading edge therapeutics to reinforce the lives of sufferers with critical retinal sicknesses. The Corporate’s lead product candidate, DURAVYU™, is an leading edge investigational sustained supply remedy for critical retinal sicknesses combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor, in next-generation bioerodible Durasert E™ era. Supported via tough protection and efficacy knowledge throughout a couple of scientific trials and indications, DURAVYU is lately being evaluated in Segment 3 pivotal trials for rainy age-related macular degeneration (rainy AMD) and diabetic macular edema (DME). Topline knowledge is predicted for rainy AMD starting in mid-2026.
The Corporate is dedicated to partnering with the retina neighborhood to reinforce affected person lives whilst growing long-term worth, with 4 authorized medication over 3 many years and tens of hundreds of eyes handled with EyePoint innovation.
EyePoint is headquartered in Watertown, Massachusetts, with a industrial production facility in Northbridge, Massachusetts.
Vorolanib is authorized to EyePoint completely via Equinox Sciences, a Betta Prescription drugs associate, for the localized remedy of all ophthalmic sicknesses outdoor of China, Macao, Hong Kong and Taiwan.
DURAVYU™ has been conditionally authorized via the FDA because the proprietary identify for EYP-1901. DURAVYU is an investigational product; it has now not been authorized via the FDA. FDA approval and the timeline for doable approval is unsure.
